The role of focal therapy in prostate cancer for kidney transplant patients
This e-course will present evidence which will demonstrate the role of focal therapy as an alternative in the management of a heterogeneous disease such as prostate cancer (PCa) in the high-risk population of kidney transplant patients and/or candidates.
| Organiser | ESU (European School of Urology) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
Organ-sparing approaches in the management of localised PCa were developed in part to overcome the morbidity associated with standard whole-gland treatment options. This can be crucial in kidney transplant patients and/or candidates.
Focal therapy was introduced and defined over two decades ago and since then, substantial developments have taken place. The evolution of patient selection; the approach to ablation; surveillance after focal therapy; and improved understanding of the biology of low-grade, low-risk PCa have mirrored the technological advancements in the field.
Speakers:
Prof. Dr. E. Lledó García (ES)
Dr. E. Barret (FR)
Dr. C. Martinez Ballesteros (ES)
Prof. Dr. J.I. Martínez Salamanca (ES)